Clin2
NCT06192160Possibly a fitRecruiting

New TB drug combinations for drug-sensitive lung TB

Pulmonary Tuberculosis

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
315 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have active TB in your lungs, confirmed by a test (Xpert) showing 'medium' or 'high' bacteria levels within the last week.
  • Your TB bacteria are sensitive to the standard drugs isoniazid and rifampin (not resistant).
  • You are not pregnant, breastfeeding, or planning pregnancy in the next year, and you agree to use effective birth control if needed.
  • You are at least 18 years old and weigh at least 35 kg (about 77 pounds).
  • Your liver, kidney, and blood counts are within acceptable ranges, and you have no serious heart rhythm issues or other major medical problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06905522Recruiting· Phase 3
Tuberculosis treatment trial for new patients

This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.

Beijing
NCT05807399Recruiting· Phase 2
Step2c trial for new, drug-susceptible lung TB

This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.

Lambaréné
NCT06114628Recruiting· Phase 2
Finding the best treatment for lung TB (PARADIGM4TB)

This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.

Chisinau
NCT07467252Not yet recruiting· Phase 2
Shorter treatment for lung tuberculosis with two existing medicines

This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.

Riyadh, Riyadh Region
NCT07076225Not yet recruiting· Phase 3
Shorter TB treatment for people 65 and older

This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.

NCT04260477Recruiting· Phase 3
Testing a new stronger TB retreatment medicine schedule

This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.

Niamey

Hear when a new Pulmonary Tuberculosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.